H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorde...
and their Chinese partner, Jiangsu Hengrui Pharmaceuticals, received a Complete Response Letter (CRL) from the U.S. FDA regarding its hepatocellular carcinoma (HCC) combination treatment candidate of rivoceranib and camrelizumab.
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorde...